PT Darya-Varia Laboratoria Tbk (DVLA.JK)
IDR 1600.0
(-1.23%)
IDR 1600.0
(-1.23%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -238.56 Billion IDR | 32.82% |
| 2022 | -355.13 Billion IDR | 36.62% |
| 2021 | -560.31 Billion IDR | -111.98% |
| 2020 | -264.32 Billion IDR | 22.04% |
| 2019 | -339.04 Billion IDR | -10.76% |
| 2018 | -306.11 Billion IDR | 32.11% |
| 2017 | -450.88 Billion IDR | -21.08% |
| 2016 | -372.37 Billion IDR | 11.81% |
| 2015 | -422.25 Billion IDR | -31.19% |
| 2014 | -321.85 Billion IDR | -5.34% |
| 2013 | -305.54 Billion IDR | -4.31% |
| 2012 | -292.91 Billion IDR | -14.2% |
| 2011 | -256.48 Billion IDR | -1.59% |
| 2010 | -252.46 Billion IDR | -37.4% |
| 2009 | -183.74 Billion IDR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -437.5 Billion IDR | -58.95% |
| 2024 Q1 | -295.15 Billion IDR | -23.72% |
| 2024 Q2 | -274.8 Billion IDR | 6.9% |
| 2023 Q4 | -238.56 Billion IDR | 29.71% |
| 2023 Q1 | -305.88 Billion IDR | 13.87% |
| 2023 Q2 | -315.04 Billion IDR | -3.0% |
| 2023 FY | -238.56 Billion IDR | 32.82% |
| 2023 Q3 | -339.39 Billion IDR | -7.73% |
| 2022 Q1 | -372.82 Billion IDR | 33.46% |
| 2022 Q2 | -551.11 Billion IDR | -47.82% |
| 2022 Q3 | -381.95 Billion IDR | 30.69% |
| 2022 Q4 | -355.13 Billion IDR | 7.02% |
| 2022 FY | -355.13 Billion IDR | 36.62% |
| 2021 Q1 | -337.5 Billion IDR | -27.69% |
| 2021 Q4 | -560.31 Billion IDR | -42.81% |
| 2021 Q3 | -392.35 Billion IDR | 6.26% |
| 2021 Q2 | -418.57 Billion IDR | -24.02% |
| 2021 FY | -560.31 Billion IDR | -111.98% |
| 2020 Q4 | -264.32 Billion IDR | 26.89% |
| 2020 Q1 | -358.23 Billion IDR | -5.66% |
| 2020 Q2 | -308.11 Billion IDR | 13.99% |
| 2020 FY | -264.32 Billion IDR | 22.04% |
| 2020 Q3 | -361.52 Billion IDR | -17.34% |
| 2019 FY | -339.04 Billion IDR | -10.76% |
| 2019 Q2 | -237.8 Billion IDR | -14.08% |
| 2019 Q4 | -339.04 Billion IDR | -1.45% |
| 2019 Q1 | -208.44 Billion IDR | 31.91% |
| 2019 Q3 | -334.2 Billion IDR | -40.54% |
| 2018 Q3 | -347.49 Billion IDR | -1.45% |
| 2018 Q2 | -342.53 Billion IDR | 13.41% |
| 2018 FY | -306.11 Billion IDR | 32.11% |
| 2018 Q1 | -395.56 Billion IDR | 12.27% |
| 2018 Q4 | -306.11 Billion IDR | 11.91% |
| 2017 Q1 | -436.35 Billion IDR | -17.18% |
| 2017 Q2 | -342.51 Billion IDR | 21.51% |
| 2017 Q3 | -373.4 Billion IDR | -9.02% |
| 2017 Q4 | -450.88 Billion IDR | -20.75% |
| 2017 FY | -450.88 Billion IDR | -21.08% |
| 2016 FY | -372.37 Billion IDR | 11.81% |
| 2016 Q4 | -372.37 Billion IDR | -11.52% |
| 2016 Q2 | -321.97 Billion IDR | 30.57% |
| 2016 Q3 | -333.92 Billion IDR | -3.71% |
| 2016 Q1 | -463.77 Billion IDR | -9.83% |
| 2015 Q3 | -448.93 Billion IDR | 2.77% |
| 2015 FY | -422.25 Billion IDR | -31.19% |
| 2015 Q4 | -422.25 Billion IDR | 5.94% |
| 2015 Q1 | -398.58 Billion IDR | -23.84% |
| 2015 Q2 | -461.73 Billion IDR | -15.84% |
| 2014 Q1 | -339.69 Billion IDR | -11.18% |
| 2014 Q3 | -253.86 Billion IDR | 24.85% |
| 2014 Q4 | -321.85 Billion IDR | -26.78% |
| 2014 Q2 | -337.83 Billion IDR | 0.55% |
| 2014 FY | -321.85 Billion IDR | -5.34% |
| 2013 Q2 | -291.71 Billion IDR | 18.98% |
| 2013 Q3 | -353.93 Billion IDR | -21.33% |
| 2013 Q4 | -305.54 Billion IDR | 13.67% |
| 2013 FY | -305.54 Billion IDR | -4.31% |
| 2013 Q1 | -360.06 Billion IDR | -22.93% |
| 2012 Q4 | -292.91 Billion IDR | 7.56% |
| 2012 FY | -292.91 Billion IDR | -14.2% |
| 2012 Q3 | -316.87 Billion IDR | 0.0% |
| 2011 FY | -256.48 Billion IDR | -1.59% |
| 2010 FY | -252.46 Billion IDR | -37.4% |
| 2009 FY | -183.74 Billion IDR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| PT Merck Tbk | -183.3 Billion IDR | -30.149% |
| PT Phapros, Tbk | 736.73 Billion IDR | 132.382% |
| PT Pyridam Farma Tbk | 897.02 Billion IDR | 126.596% |
| PT Industri Jamu dan Farmasi Sido Muncul Tbk | -820.73 Billion IDR | 70.932% |
| PT Tempo Scan Pacific Tbk | -2577.85 Billion IDR | 90.745% |